TIDMDVRG

RNS Number : 3460W

Deepverge PLC

17 April 2023

17 April 2023

DeepVerge plc

("DeepVerge" or "the Company" or "the Group")

2022 revenue update - revision

DeepVerge (AIM: DVRG), the environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, provides the following trading update.

On 9 January 2023 the Company announced that it expected 2022 (unaudited) revenues to be approximately GBP17.2m. Following the board change announced on 6 February 2023, and the appointment of a new Chief Financial Officer on 7 February 2023, the new management team has undertaken a comprehensive review of all major contracts.

Whilst further analysis continues, based on the current available information and analysis to date, it is clear that revenues for a number of contracts have been incorrectly recognised in excess of works completed and therefore revenues for 2022 under the relevant accounting standard IFRS15 are expected to be approximately 45-50% of the GBP17.2m revenue figure provided by the previous executive management team and notified to the market.

The vast majority of the revenue shortfall in 2022 is now expected to be recognised in 2023, although some is unlikely to be realised.

Following the above review, the Company can confirm that the current order book for Modern Water and Glanaco exceeds GBP10m, all of which is expected to be deliverable, and recognised as turnover, in 2023 and 2024. Further contracts are being sought, and, if tendering is successful, will be announced in due course, with some expected imminently.

The current cash balance is approximately GBP1m, and although requiring working capital to be tightly managed is expected to remain sufficient for the Company to continue as a going concern. The Company is exploring funding options including trade finance as a stronger balance sheet would enable the Company to accelerate delivery of some existing contracts and increase confidence in seeking new business.

The Company will make further announcements in due course.

Ross Andrews, Chairman, commented:

"Whilst it is extremely disappointing that 2022 revenues are likely to be so far below the figures provided by the previous executive management team, I'm confident that the new management has robust plans in place to deliver the order book during 2023 and 2024."

 
                            Nigel Burton, Interim 
 DeepVerge plc               CEO                     +44 (0) 7785 234447 
 SPARK Advisory Partners 
  Limited                                            +44 (0) 113 370 
  (Nominated Adviser)       Neil Baldwin              8974 
                           -----------------------  -------------------- 
 Turner Pope Investments    Andy Thacker/James       +44 (0) 20 3657 
  (TPI) Limited (Broker)     Pope                     0050 
                           -----------------------  --------------------

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFSEFMEDSEEL

(END) Dow Jones Newswires

April 17, 2023 02:00 ET (06:00 GMT)

Integumen (LSE:SKIN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Integumen Charts.
Integumen (LSE:SKIN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Integumen Charts.